# OnCo record rcc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/rcc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "rcc" ;
  schema:name "Renal cell carcinoma"@en ;
  schema:alternateName "RCC"@en ;
  schema:description "Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."@en ;
  schema:url <https://onco.cc/cancers/rcc/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Renal_cell_carcinoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1164529> ;
  schema:citation <https://www.cancer.gov/types/kidney/hp/kidney-treatment-pdq>, <https://www.annalsofoncology.org/article/S0923-7534(24)01516-3/fulltext> ;
  onco:tag "gu" ;
  onco:related <https://onco.cc/collections/src-urotoday/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/allogeneic-cell-therapy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/partial-nephrectomy-active-surveillance/>, <https://onco.cc/technologies/caix-pet/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/radioimmunotherapy/> ;
  onco:targets <https://onco.cc/targets/hif2a/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/cd70/>, <https://onco.cc/targets/cdh6/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/akt/> ;
  onco:companies <https://onco.cc/companies/scancell/>, <https://onco.cc/companies/vyriad/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/exelixis/>, <https://onco.cc/companies/eisai/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/aveo/>, <https://onco.cc/companies/telix/>, <https://onco.cc/companies/roche-genentech/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/md-anderson/>, <https://onco.cc/institutions/dana-farber/>, <https://onco.cc/institutions/gustave-roussy/>, <https://onco.cc/institutions/cleveland-clinic/> ;
  onco:pathways <https://onco.cc/pathways/hif-vhl/>, <https://onco.cc/pathways/vegf-angiogenesis/>, <https://onco.cc/pathways/renal-cell-carcinoma-signalling/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:terms <https://onco.cc/terms/imdc-risk/>, <https://onco.cc/terms/sarcomatoid-rcc/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/oligometastatic/>, <https://onco.cc/terms/nephrectomy/> ;
  onco:trials <https://onco.cc/trials/nct07227402/>, <https://onco.cc/trials/nct07489495/>, <https://onco.cc/trials/renaviv/>, <https://onco.cc/trials/nct04523272/>, <https://onco.cc/trials/nct03873402/>, <https://onco.cc/trials/nct04810078/>, <https://onco.cc/trials/nct05043090/>, <https://onco.cc/trials/nct07011719/>, <https://onco.cc/trials/nct03091192/>, <https://onco.cc/trials/nct04586231/>, <https://onco.cc/trials/nct05899049/>, <https://onco.cc/trials/nct07197580/> ;
  onco:people <https://onco.cc/people/arnaud-mejean/> ;
  onco:journals <https://onco.cc/journals/clinical-genitourinary-cancer/>, <https://onco.cc/journals/urologic-oncology/> ;
  onco:pipeline <https://onco.cc/drugs/raludotatug-deruxtecan/>, <https://onco.cc/drugs/intismeran-autogene/>, <https://onco.cc/drugs/pf-08634404/>, <https://onco.cc/drugs/zanzalintinib/>, <https://onco.cc/drugs/abexinostat/>, <https://onco.cc/drugs/al8326/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/tqb2450/>, <https://onco.cc/drugs/ibi363/>, <https://onco.cc/drugs/jk08/>, <https://onco.cc/drugs/adi-270/>, <https://onco.cc/trials/litespark-022/>, <https://onco.cc/technologies/caix-pet/>, <https://onco.cc/ideas/idea-caix-theranostics/>, <https://onco.cc/ideas/idea-adjuvant-selection-rcc/>, <https://onco.cc/drugs/belzutifan/>, <https://onco.cc/pairings/risk-directed-first-line-rcc/>, <https://onco.cc/pairings/io-rechallenge-caution-rcc/>, <https://onco.cc/technologies/allogeneic-cell-therapy/>, <https://onco.cc/technologies/partial-nephrectomy-active-surveillance/>, <https://onco.cc/technologies/radioimmunotherapy/> ;
  onco:standardOfCare <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/belzutifan/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/belzutifan/>, <https://onco.cc/technologies/partial-nephrectomy-active-surveillance/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-564/>, <https://onco.cc/drugs/belzutifan/>, <https://onco.cc/trials/litespark-022/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/trials/checkmate-214/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/axitinib/>, <https://onco.cc/trials/keynote-426/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/trials/checkmate-9er/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/trials/clear/>, <https://onco.cc/pairings/risk-directed-first-line-rcc/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/axitinib/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/terms/imdc-risk/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/belzutifan/>, <https://onco.cc/trials/litespark-005/>, <https://onco.cc/drugs/tivozanib/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/pairings/io-rechallenge-caution-rcc/>, <https://onco.cc/trials/contact-03/>, <https://onco.cc/trials/tinivo-2/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/belzutifan/> .